Specialty drug maker Spectrum Pharmaceuticals Inc. said Monday a midstage study of its developing prostate cancer drug met its primary goal of safety and suppressing testosterone levels.
The drug candidate, called Ozarelix, is aimed at treating prostate cancer, which is the second leading cause of cancer-related deaths in men. In a Phase II clinical trial, a 130-milligram dose given every 4 weeks provided continuous testosterone suppression in patients between day 8 and day 85 of the study. The drug also met a secondary goal, the reduction of a prostate specific antigen.
Spectrum received an exclusive license from AEterna Zentaris in 2004 to develop and market Ozarelix in North America and India. The company will receive half of any payments or profits from sales of the drug in Japan.
The drug is also being developed for benign prostatic hypertrophy and hormone-dependent prostate cancer.
Shares of Spectrum fell a penny to $5.45 on the Nasdaq in morning trading.Copyright 2006 Associated Press.